Phytopharm plc has been awarded a grant by the Technology Strategy Board to provide funding to support the evaluation of Myogane™ in an in vivo preclinical model of glaucoma.
Myogane™ has the potential to be a neuro-protectant treatment of glaucoma. Glaucoma is a neurodegenerative disease of the eye affecting 60 million people and is the second leading cause of blindness worldwide. Current treatments of glaucoma are predominantly targeted at reducing intra ocular pressure within the eye, however the remains a major unmet medical need for treatments which can slow the underlying neurodegenerative disease process.
Myogane™ has demonstrated neuro-protective and neuro-restorative effects in a range of neuronal cell types including retinal ganglion cells, which are the cells affected in glaucoma. Myogane™ exhibits it’s effect via the modulation of neurotrophic factors, naturally occurring proteins which protect and promote the growth of neurones and which have been shown to be effective in protecting against neurodegeneration in a number of models of glaucoma.
The study, if positive, will support the further clinical development of Myogane™ in glaucoma. Myogane™ is a small molecule drug which has been shown to have good oral bioavailability when dosed once daily in Phase I studies.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
